A Randomized Trial of LOVAZA in Pediatric Sickle Cell Disease (SCD)
Recruitment status was Not yet recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the study is to determine the effectiveness of LOVAZA (fish oil capsules) to decrease inflammation in children and adolescents with Sickle Cell Disease (SCD). It has been found that besides the damage caused by sickle red blood cells themselves, the inflammatory response that occurs in SCD patients could potentially play a significant role in the occurrence of painful episodes or pain crises. The investigators will also study whether the subject/caregiver feels that there is an improvement in the child's quality of life by taking the medication. Besides the effect of LOVAZA on inflammation,the investigators are also testing whether the drug will have a beneficial effect on blood clotting ability (which is known to be increased in SCD) and on the anemia (low red blood cells) that is part of the disease entity.
| Condition | Intervention | Phase |
|---|---|---|
|
Sickle Cell Disease HEMOGLOBIN SS Hemoglobin S Beta-0 Thalassemia Inflammation Quality of Life |
Dietary Supplement: Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) Other: Placebo Capsules |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Phase II Randomized Double-Blind Placebo-Controlled Trial of the Omega-3 Fatty Acids Eicosapentaenoic (EPA) and Docosahexaenoic Acid (DHA) in Pediatric Sickle Cell Disease (SCD) |
- To determine whether supplementation with LOVAZA will exert an anti-inflammatory effect by decreasing levels of the inflammatory biomarker high sensitivity C Reactive Protein (hsCRP) in children and adolescents with Sickle Cell Disease (SCD). [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- To determine whether supplementation with LOVAZA will increase health-associated quality of life (QoL) responses as they relate to clinical vasocclusive events (VOC) in children and adolescents with Sickle Cell Disease (SCD). [ Time Frame: 6 months ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 48 |
| Study Start Date: | October 2010 |
| Estimated Study Completion Date: | March 2012 |
| Estimated Primary Completion Date: | March 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: LOVAZA |
Dietary Supplement: Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)
Eicosapentaenoic Acid (EPA)/Docosahexaenoic Acid (DHA) 30mg/kg (LOVAZA capsules) given by mouth daily for 6 months.
Other Names:
|
| Placebo Comparator: Placebo capsule |
Other: Placebo Capsules
Placebo capsules given by mouth daily for 6 months.
Other Name: - Placebo
|
Eligibility| Ages Eligible for Study: | 10 Years to 19 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Subjects who meet all of the following criteria are eligible for enrollment into the study:
- Participant has signed the informed consent/assent with parent signing informed consent as age appropriate.
- Established diagnosis of HbSS or HbSβo Thal.
- History of ≥3 vasocclusive pain events in preceding 12 months.
- Regular compliance with comprehensive care.
- Aged 10 years or greater and less than 20 years.
- At enrollment, subject should be in his/her steady or baseline state.
Exclusion Criteria
- Subjects with Hb levels <5.5gm/dL.
- Inability to take or tolerate oral medications.
- Poor compliance with previous treatment regimens.
- Hepatic dysfunction (SGPT also known as ALT >2X upper limit of normal or conjugated bilirubin >2X the patients baseline within the last 6 weeks).
- Renal dysfunction (A creatinine level within the past 6 weeks of ≥ 1.0mg/dL for children and ≥ 1.2mg/dL for a subject ≥ 18 years of age).
- Allergy to fish or shell fish.
- Triglyceride levels <80mg/dL.
- Pregnancy.
- Chronic Transfusion Therapy.
- Transfusion within the last 30 days.
- Persistent pain from sickle-complications (e.g. avascular necrosis).
- A vasocclusive pain episode lasting longer than 2 weeks or >12 pain episodes in preceding year.
- Daily narcotic usage.
- Treatment with any investigational drug or regular fish oil supplementations in last 60 days.
- Currently receiving another investigational agent, or on such an agent with the last 60 days.
- Dosage changes in preceding 3 months if on hydroxyurea.
- Bleeding disorder or patient on concomitant anti-coagulation.
- Conditional or abnormal TCD result or stroke.
- Other chronic illness that could adversely affect subjects performance such as HIV or TB.
- Children in Care (CiC): A child in care is a child who has been placed under the control or protection of an agency, organization, institution or entity by the courts, the government or a government body, acting in accordance with powers conferred on them by law or regulation.
Contacts and Locations| Contact: Marie Stuart, M.D. | 215-955-1819 cell-215.847.1471 | marie.stuart@jefferson.edu |
| United States, Pennsylvania | |
| Thomas Jefferson University Hospital | Not yet recruiting |
| Philadelphia, Pennsylvania, United States, 19107 | |
| Principal Investigator: Marie Stuart, M.D. | |
| Sub-Investigator: Suba Krishnan, M.D. | |
| Sub-Investigator: B.N. Yamaja Setty, Ph.D. | |
| St. Christopher's Hospital for Children, Drexel University | Not yet recruiting |
| Philadelphia, Pennsylvania, United States, 19134-1095 | |
| Contact: Norma Lerner, M.D. 215-427-5261 norma.lerner@tenethealth.com | |
| Contact: Maureen Meier, RN, CCRC 215-427-3835 maureen.meier@tenethealth.com | |
| Sub-Investigator: Maureen Meier, RN, CCRC | |
| Principal Investigator: | Marie Stuart, M.D. | Thomas Jefferson University |
More Information
Publications:
| Responsible Party: | Marie Stuart, MD, Thomas Jefferson University |
| ClinicalTrials.gov Identifier: | NCT01202812 History of Changes |
| Other Study ID Numbers: | 10F.161 |
| Study First Received: | September 14, 2010 |
| Last Updated: | October 22, 2010 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Thomas Jefferson University:
|
Sickle Cell Anemia Sickle Cell Disease Hemoglobin SS Disease Hemoglobin S beta-0 Thalassemia Inflammation Quality of Life Sickle Thalassemia C-Reative Protein Hemolytic Anemia |
Hemostasis Biomarkers Coagulation Omega-3 Fatty Acids Eicosapentaenoic Acid Docosahexaenoic Acid Fish Oils Drug: Placebo Drug: LOVAZA |
Additional relevant MeSH terms:
|
Anemia, Sickle Cell Inflammation Thalassemia Anemia, Hemolytic, Congenital Anemia, Hemolytic |
Anemia Hematologic Diseases Hemoglobinopathies Genetic Diseases, Inborn Pathologic Processes |
ClinicalTrials.gov processed this record on May 19, 2013